The Fly | NCEL

Yesterday

NewcelX initiated with bullish view at Laidlaw, here's why

NCEL

Yesterday, 4:57 AM

Over a week ago

NewcelX completes Type B Pre-IND meeting with FDA for NCEL-101

Jul 1, 9:33 AM

NewcelX submits NCEL-101 pre-investigational new drug briefing package to FDA

May 27, 7:58 AM

NewcelX files to sell 2.26M common shares for holders

NCEL

May 11, 5:07 PM

NewcelX announces release of updated presentation on Type 1 Diabetes program

Apr 20, 7:38 AM

NewcelX announces research agreement with Eledon Pharmaceuticals

Mar 9, 7:06 AM

No more stories

Proprietary Extended-Release Formulation: NLSP has developed and patented an extended-release formulation of Mazindol (Mazindol ER), potentially offering improved pharmacokinetics and patient compliance over immediate-release versions.

Unique Mechanism of Action: Mazindol ER acts as a triple monoamine reuptake inhibitor (norepinephrine, dopamine, serotonin), providing a distinct pharmacological profile that could differentiate it from existing and pipeline competitors in CNS disorders.

Late-Stage Clinical Development: With its lead candidate, Mazindol ER (Quilience®), in Phase 3 clinical trials for narcolepsy, NLSP is closer to market commercialization, reducing development risk compared to earlier-stage assets.

Clinical Trial Outcomes Risk: The success of Nls Pharmaceutics Ltd. is heavily dependent on the positive outcomes of ongoing and future clinical trials for its product candidates, and there is no guarantee these trials will meet their endpoints or demonstrate efficacy and safety.

Regulatory Approval Uncertainty Risk: Even if clinical trials are successful, obtaining the necessary regulatory approvals from health authorities like the FDA or EMA for its drug candidates is a complex, lengthy, and uncertain process, which could be delayed or denied.

Funding and Liquidity Risk: As a clinical-stage biopharmaceutical company with no current revenue from product sales, NLSP relies on external financing to fund its operations and drug development, posing a risk of insufficient capital for future activities.